The cancer cells are surviving and thriving because the entire neighborhood has been transformed.
At the University of Oklahoma, researchers have uncovered something more unsettling than a statistical correlation: obesity does not merely raise the odds of breast cancer, it rewires the biological logic by which early tumors become invasive ones. The tumor's neighborhood — immune cells, supporting tissue, metabolic signals — is transformed into a cooperative system that serves the cancer's advance. As obesity rates approach half the American population by 2030, this finding asks medicine to reckon with the possibility that for many women, the disease being treated is not quite the disease being understood.
- Obesity doesn't just raise cancer risk — it changes the fundamental biology of how breast cancer progresses, creating a distinct disease pathway driven by inflammation, immune cell infiltration, and metabolic shifts.
- An enzyme called SULF2 has been found at elevated levels in obese patients' tumors, pointing toward a molecular mechanism that researchers believe plays a central role in driving early tumors toward invasion.
- The inability to predict which DCIS patients will progress to invasive cancer means nearly all receive aggressive treatment — surgery, radiation, hormone therapy — even when half may never have needed it.
- With obesity projected to affect 50% of Americans by 2030, the gap between rising disease burden and treatment strategies designed for a different biological reality is widening fast.
- Researchers are now asking whether targeting a single cell type in the tumor's cooperative network could break the entire chain of progression — a question that could reshape how obesity-related breast cancer is treated.
Researchers at the University of Oklahoma have found that obesity does not simply increase a woman's risk of breast cancer — it fundamentally changes how the disease develops. In women without obesity, early tumors follow a recognizable progression. In women with obesity, something different unfolds: the tumor environment becomes inflamed, immune cells arrive and paradoxically accelerate growth, cancer cells grow more resilient under stress, and their metabolism shifts in ways that favor invasion. These are not variations on the same disease. They are different biological rules.
Published in The American Journal of Pathology, the research describes what amounts to a cooperative network. Cancer cells recruit and reprogram the surrounding tissue — epithelial cells, immune cells, supporting structures — into a unified system that pushes early tumors toward invasion. Co-lead author Bethany Hannafon described it as the entire neighborhood being transformed to support the cancer's survival. Her co-lead, Elizabeth Wellberg, raised the question that follows: if progression depends on cooperation between multiple cell types, could targeting just one of them break the chain? The team also identified elevated levels of the enzyme SULF2 in obese patients' tumors, flagging it as a focus for future investigation.
The clinical urgency is real. Women diagnosed with ductal carcinoma in situ — an early, noninvasive breast cancer — face a difficult uncertainty: roughly half will progress to invasive disease, and half will not. Because physicians cannot yet distinguish between them, nearly all receive aggressive treatment. The result is widespread overtreatment, with women enduring surgery, radiation, and hormone therapy for a disease that may never have advanced. Identifying which patients, particularly those with obesity, are truly at risk could spare many from unnecessary procedures.
The research arrives as obesity rates in the United States climb toward a projected 50% by 2030. First author Cole Hladik emphasized that understanding a patient's metabolic health alongside tumor biology has become essential. Breast cancer survival has improved over two decades, yet the number of women diagnosed with invasive disease has not fallen — and for women with obesity, the disease may be advancing through pathways that existing treatments were never designed to address.
A team of researchers at the University of Oklahoma has identified a troubling mechanism: obesity does not simply increase the risk of breast cancer. It fundamentally rewires how the disease develops, turning early, contained tumors into aggressive invasive cancers through a cascade of biological changes that do not occur in women without obesity.
The distinction matters because it reveals why obesity is such a powerful risk factor for invasive breast cancer—and it opens a window onto a clinical problem that affects thousands of women. When breast cancer develops in women without obesity, the disease follows a recognizable path: cancer cells divide rapidly and gain the ability to invade surrounding tissue. But in women with obesity, the researchers found something different. The tumor environment becomes inflamed. Immune cells arrive and, counterintuitively, accelerate tumor growth rather than halt it. The cancer cells themselves become more resilient, better able to survive under stress. Their metabolism shifts—the way they consume nutrients for energy changes in ways that favor progression. These are not the same biological signals. They are a different disease, operating by different rules.
The research, published in The American Journal of Pathology, suggests that obesity creates what amounts to a cooperative network. Cancer cells do not act alone. They recruit and reprogram the cells around them—the epithelial cells, the immune cells, the supporting tissue—into a unified system that pushes early tumors toward invasion. As Bethany Hannafon, an assistant professor in the Department of Obstetrics and Gynecology at OU College of Medicine and co-lead author, explained it: the cancer cells are surviving and thriving because the entire neighborhood has been transformed to support them. Elizabeth Wellberg, her co-lead author in the Department of Pathology, framed the question that follows: if the progression toward invasive cancer depends on cooperation between multiple cell types, could a drug or intervention targeting just one of those cell types break the entire chain?
The researchers also identified elevated levels of an enzyme called Sulfatase 2, or SULF2, in the tumor cells of women with obesity. This enzyme appears to play a central role in cancer progression and will be a focus of future investigation.
The clinical stakes are high. Many women are diagnosed with ductal carcinoma in situ, or DCIS—an early, noninvasive form of breast cancer. About half of these women will eventually develop invasive ductal carcinoma that spreads into surrounding tissue. The other half will not. Yet because physicians cannot predict which women will progress, nearly all receive the same aggressive treatment: surgery, radiation, and sometimes hormone therapy. This creates a significant problem of overtreatment. Women undergo procedures and endure side effects for a disease that may never have advanced. If researchers could identify which patients are truly at risk—particularly those whose obesity may be accelerating progression—unnecessary treatments could be avoided.
The timing of this research aligns with a troubling demographic shift. Obesity rates in the United States are rising sharply. By 2030, researchers project that half of all Americans will be obese. Cole Hladik, the study's first author, emphasized that this statistic underscores why understanding a patient's metabolic health alongside tumor biology has become essential. Breast cancer survival rates have improved over the past two decades, yet the number of women diagnosed with invasive breast cancer has not declined. The disease persists, and in women with obesity, it may be progressing through pathways that current treatment approaches were not designed to address.
Citações Notáveis
In women with obesity, there is cooperation between all the cell types, not just the cancer cells, which helps an early pre-cancer to become an invasive breast cancer.— Elizabeth Wellberg, assistant professor, Department of Pathology, OU College of Medicine
Obesity is on the rise—50% of Americans are expected to be obese by 2030. That statistic further highlights the importance of considering a patient's metabolic health alongside the biology of the tumor itself.— Cole Hladik, first author of the study
A Conversa do Hearth Outra perspectiva sobre a história
Why does obesity change the way cancer develops? Is it just that obese women have more inflammation generally?
It's more specific than that. The obesity creates an environment where the tumor cells and the cells around them start cooperating in ways that don't happen otherwise. The immune cells that arrive aren't fighting the cancer—they're feeding it.
So the immune system is actually helping the cancer grow?
In this context, yes. The immune cells that infiltrate the tumor are promoting its growth rather than suppressing it. It's a perversion of the immune response.
You mentioned this enzyme, SULF2. What does it do?
We don't fully know yet. But it's elevated in obese patients' tumors, and it appears to be important for the cancer to progress from early to invasive. It's one of the next pieces researchers want to understand.
If half of women with early breast cancer will never develop invasive disease, why does everyone get treated the same way?
Because we have no way to tell which half will progress. So doctors treat everyone as if they will. It's a safety-first approach, but it means a lot of women are getting surgery and radiation they may not have needed.
And obesity might be a way to identify who's actually at risk?
Potentially. If obesity is driving a different biological pathway to invasion, understanding that pathway might let us predict which obese women with early cancer will progress—and which won't.
What happens next?
More research into SULF2, more investigation into how to interrupt the cooperation between cancer cells and their environment. And the practical question: can we develop a test that tells us which women with early cancer actually need aggressive treatment?